SEC Filing Summary: DelMar Pharmaceuticals, Inc. Form 10-K
Filing/period clarification: The supplied filing is DelMar Pharmaceuticals, Inc.’s annual report for the fiscal year ended June 30, 2015, filed September 3, 2015. It does not identify Tuhura Biosciences, Inc. or report a standalone 2014 Q4 period; the requested company and period therefore do not match the source document.
Business context and reporting period
DelMar was a clinical-stage cancer drug developer focused primarily on VAL-083 for refractory glioblastoma (GBM). VAL-083 was approved in China for lung cancer and chronic myelogenous leukemia (CML), but had no approval outside China. The company reported on a U.S. GAAP basis in U.S. dollars and changed its fiscal year-end from December 31 to June 30; the comparative periods are the years ended June 30, 2015 and June 30, 2014.
Financial performance and position
| Metric | FY ended June 30, 2015 | FY ended June 30, 2014 |
|---|---|---|
| Product revenue | No product revenue reported | No product revenue reported |
| Research and development | $2.56 million | $2.12 million |
| General and administrative | $2.17 million | $3.13 million |
| Net loss (income) | $4.80 million loss | $3.13 million income |
| Operating cash used | $3.85 million | $4.00 million |
| Cash and cash equivalents at year-end | $1.75 million | $4.76 million |
| Working capital at year-end | $1.72 million | $4.70 million |
| Total assets at year-end | $2.58 million | $5.00 million |
| Total stockholders’ equity at year-end | $0.51 million | $0.88 million |
Operating margins are not meaningful because the company had no product revenue. The filing reports no conventional loan payable at June 30, 2015: a $278,530 related-party loan was exchanged for Series A preferred shares in September 2014. Year-end liabilities included a $1.03 million derivative liability, $179,445 stock-option liability and $853,085 in current payables and accrued liabilities. The preferred shares carry a 3% annual dividend.
Material changes and unusual items
- Net results shifted from $3.13 million income in FY2014 to a $4.80 million loss in FY2015. FY2014 income was substantially affected by an $8.30 million non-cash gain from revaluing warrant derivative liabilities; the corresponding FY2015 gain was $179,170. FY2015 also included a $249,062 loss on warrant exchanges.
- R&D expense rose 21%, principally due to clinical development and intellectual-property costs. G&A expense fell 31%; management attributed much of the decline to lower share-based compensation, while G&A excluding that compensation was broadly stable.
- Cash declined by $3.01 million during FY2015. Warrant exercises generated $1.40 million net financing proceeds, compared with $2.48 million in FY2014.
- After year-end, a registered offering raised approximately $2.57 million gross and $1.92 million net, issuing 4.28 million common shares and warrants. The lower offering price also reduced the exercise price of certain outstanding warrants.
Outlook, commentary and principal risks
- Liquidity and going concern: The auditor’s report includes a going-concern emphasis, and management states there is substantial doubt about the company’s ability to continue without additional funding. The company had an accumulated deficit of $23.47 million, no product revenue and $1.75 million in cash at year-end. Management planned to seek further equity financing and/or strategic partnerships; success was not assured.
- Clinical development: In an open-label Phase I/II GBM study, 30 patients were enrolled across dose cohorts. Interim results showed median overall survival of 9 months in higher-dose cohorts (at least 30 mg/m²/day) versus 5 months in lower-dose cohorts (up to 5 mg/m²/day). These are preliminary observations from small cohorts, not definitive evidence of efficacy. Thrombocytopenia was dose-limiting at 50 mg/m²/day; the company reported no drug-related severe adverse events in the interim results described.
- The company began a Phase II expansion cohort, planned to enroll about 14 patients at 40 mg/m²/day, with a small 45 mg/m²/day cohort also contemplated. Management said a later registration-directed study could require additional funding and that timing and design depended on expansion data and FDA discussions.
- For China, the company planned a post-market lung-cancer study with Guangxi Wuzhou Pharma, which was responsible for trial costs under the collaboration agreement. The filing also describes potential development in CML and other cancers, subject to resources.
- Key risks include clinical failure or safety issues, regulatory delays or denial, dependence on additional financing, reliance on third-party trial and manufacturing partners, single-source clinical supply risk, competition, uncertain commercialization and reimbursement, and patent and intellectual-property challenges. VAL-083 requires compliant cGMP manufacturing for potential U.S. approval.
- The company reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation. No legal proceedings were reported.
Most important facts for investors to verify
- Confirm the intended issuer and reporting period: this source is DelMar FY2015, not Tuhura Biosciences or 2014 Q4.
- Review subsequent financing proceeds, offering costs, cash runway and any additional capital raised after the filing date.
- Check updated GBM expansion-cohort results, enrollment, adverse events, FDA feedback and the status and funding of any registration-directed trial.
- Assess warrant and option overhang, potential dilution, and the impact of warrant repricing and exchanges on the share count.
- Verify the terms and progress of the China collaboration and studies, and whether manufacturing can meet U.S. and other target-market requirements.
- Consider the auditor’s going-concern emphasis and the fact that continued operations depended on financing or partnership arrangements that were not assured.